Yammine, S. G.
Huybrechts, I.
Biessy, C.
Dossus, L.
Panico, S.
Sánchez, M. J.
Benetou, V.
Turzanski-Fortner, R.
Katzke, V.
Idahl, A.
Skeie, G.
Olsen, K. Standahl
Tjønneland, A.
Halkjaer, J.
Colorado-Yohar, S.
Heath, A. K.
Sonestedt, E.
Sartor, H.
Schulze, M. B.
Palli, D.
Crous-Bou, M.
Dorronsoro, A.
Overvad, K.
Gurrea, A. Barricarte
Severi, G.
Vermeulen, R. C.H.
Sandanger, T. M.
Travis, R. C.
Key, T.
Amiano, P.
Van Guelpen, B.
Johansson, M.
Sund, M.
Tumino, R.
Wareham, N.
Sacerdote, C.
Krogh, V.
Brennan, P.
Riboli, E.
Weiderpass, E.
Gunter, M. J.
Chajès, V.
Funding for this research was provided by:
Institut National Du Cancer (2016-184)
ARC (2019-DOC4)
Centre International de Recherche sur le Cancer
Article History
Received: 29 June 2022
Accepted: 6 February 2023
First Online: 16 February 2023
Declarations
:
: All participants provided written informed consent to participate in the EPIC study. The EPIC study was approved by the Ethics Committee of the International Agency for Research on Cancer (IARC) and all EPIC centers. The present study has been approved by the IARC Ethics Committee (IEC meeting 2015-05) and the EPIC Steering Committee with representation from IARC, Imperial College, and the EPIC centers. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: The authors declare that they have no competing interests.
: Where authors are identified as personnel of the International Agency for Research on Cancer/ World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer / World Health Organization.